DrugPatentWatch Database Preview
Patent: 7,645,449
» See Plans and Pricing
Summary for Patent: 7,645,449
| Title: | Sensitizing cells for apoptosis by selectively blocking cytokines |
| Abstract: | The invention refers to the use of a cytokine antagonist which modulates the expression and/or the function of a cytokine, particularly a Th2 helper cell cytokine, in a cell and causes the down-regulation of anti-apoptotic proteins in said cell through the cytokine modulation for sensitizing cells for apoptosis. In particular, the cells that can be treated with the cytokine antagonists are drug-resistant cancer cells which fail to undergo apoptosis. |
| Inventor(s): | Stassi; Giorgio, N/A (IT-90127 Palermo, IT), Todaro; Matilde, N/A (IT-90127 Palermo, IT) |
| Assignee: | |
| Application Number: | 10/544,794 |
| Patent Claims: | see list of patent claims |
Details for Patent 7,645,449
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | HERCEPTIN HYLECTA | trastuzumab; hyaluronidase-oysk | INJECTABLE;SUBCUTANEOUS | 761106 | 001 | 2019-02-28 | Start Trial | 2023-02-07 | RX | search | ||
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 002 | 2017-06-22 | Start Trial | 2023-02-07 | RX | Orphan | search | |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | Start Trial | 2023-02-07 | RX | Orphan | search | |
| Genentech | HERCEPTIN | trastuzumab | VIAL; INTRAVENOUS | 103792 | 001 | 1998-09-25 | Start Trial | 2023-02-07 | RX | Orphan | search | |
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 002 | 1997-11-26 | Start Trial | 2023-02-07 | RX | search | ||
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 001 | 1997-11-26 | Start Trial | 2023-02-07 | RX | search | ||
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 7,645,449
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2004069274 | Start Trial |
| United States of America | 2006257401 | Start Trial |
| United States of America | 2010099742 | Start Trial |
| Japan | 2006519190 | Start Trial |
| Spain | 2303630 | Start Trial |
| European Patent Office | 1444989 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
